Getinge stock (SE0000202624): Medical device leader expands neonatal ventilator portfolio

Getinge AB strengthens position in critical care with advanced neonatal ventilator technology as global market grows at 4.63% annually through 2031.

Getinge AB, a Swedish medical technology company, continues to expand its presence in the neonatal ventilator market as demand for advanced respiratory care solutions accelerates globally. The company's Servo Type ventilators, which incorporate NAVA and Edi monitoring technology, represent a significant offering in a market projected to grow at a compound annual growth rate of 4.63% between 2025 and 2031, according to GlobeNewswire as of May 14, 2026.

The neonatal ventilator segment represents a critical component of Getinge's Acute Care Therapies division, which serves operating rooms, intensive-care units, and sterilization departments across multiple geographies. The company's focus on real-time diaphragm monitoring and hybrid ventilation approaches positions it within a market segment where consumables and accessories are expected to capture significant demand alongside core equipment sales.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge AB (publ)
• Sector/industry: Medical devices, healthcare equipment
• Headquarters/country: Sweden
• Core markets: Operating rooms, intensive-care units, sterilization departments globally
• Key revenue drivers: Acute Care Therapies, Life Science, Surgical Workflows segments
• Home exchange/listing venue: Nasdaq Stockholm (GETIBS)
• Trading currency: SEK

Getinge AB: core business model

Getinge operates as a diversified medical technology provider serving healthcare institutions worldwide. The company's three primary segments—Acute Care Therapies, Life Science, and Surgical Workflows—address complementary needs across hospital environments. Acute Care Therapies focuses on critical care equipment including extracorporeal membrane oxygenation (ECMO), mechanical ventilation systems, advanced patient monitoring, and ICU infrastructure. This segment directly supports the neonatal ventilator market expansion, where specialized respiratory support for newborns represents a high-value application area requiring precision engineering and real-time monitoring capabilities.

The company's market position reflects both organic growth in core therapeutic areas and strategic positioning within expanding healthcare segments. With a market capitalization of approximately SEK 52.16 billion, Getinge ranks among the significant players in medical device manufacturing, competing alongside established names in sterilization, infection prevention, and critical care equipment. The Swedish headquarters provides access to European regulatory frameworks and manufacturing expertise, while international operations extend market reach across North America, Europe, and Asia-Pacific regions.

Main revenue and product drivers for Getinge AB

Neonatal ventilation represents one of several high-growth segments within Getinge's Acute Care Therapies portfolio. The Servo Type ventilators incorporate NAVA (Neurally Adjusted Ventilatory Assist) and Edi (Electrical Diaphragm Activity) monitoring, technologies that enable clinicians to assess real-time diaphragm function in premature and critically ill newborns. This capability addresses a clinical need for non-invasive and hybrid ventilation approaches, which are gaining adoption as healthcare systems seek to reduce ventilator-associated complications and improve patient outcomes in neonatal intensive care units.

Beyond neonatal equipment, Getinge's revenue streams include ECMO systems for extracorporeal life support, advanced monitoring platforms for ICU environments, and sterilization solutions for surgical and laboratory settings. The Life Science segment serves pharmaceutical and biotech manufacturers with sterilization and contamination control products, while Surgical Workflows addresses operating room efficiency through integrated equipment and workflow solutions. This diversification across acute care, life sciences, and surgical applications provides revenue stability and exposure to multiple healthcare spending categories, including both capital equipment purchases and recurring consumables and service revenue.

Why Getinge AB matters for US investors

Getinge's exposure to the neonatal ventilator market and broader critical care segment carries relevance for US-based equity investors through multiple channels. First, the United States represents one of the world's largest healthcare equipment markets, with significant spending on neonatal intensive care infrastructure across hospital systems. Second, Getinge's Nasdaq Stockholm listing provides international diversification within healthcare technology, offering exposure to European manufacturing expertise and global distribution networks. Third, the company's focus on infection prevention and sterilization solutions aligns with ongoing US healthcare priorities around patient safety and contamination control, particularly in post-pandemic healthcare environments where infection prevention remains a budgetary priority.

Conclusion

Getinge AB's positioning within the expanding neonatal ventilator market reflects broader industry trends toward advanced respiratory monitoring and non-invasive care approaches. The company's Servo Type ventilators, incorporating NAVA and Edi technologies, address clinical needs within a market segment projected to grow at 4.63% annually through 2031. While the neonatal ventilator market represents one component of Getinge's diversified Acute Care Therapies segment, the expansion of this product category underscores the company's strategic alignment with healthcare system priorities around critical care innovation. Investors should monitor quarterly earnings reports and product pipeline announcements for evidence of market share gains and revenue contribution from advanced ventilation solutions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.